Skip to main content

Noelia Díaz Troyano

Institutions of which they are part

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Noelia Díaz Troyano

Institutions of which they are part

Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT)

IP: -
Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Maria Francesca Cortese, Sandra Mancilla Zamora
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 01173
Duration: 01/01/2022 - 30/06/2025

Estudio de la quasiespecies del gen X en ARN circulante del virus de la hepatitis B (ARN-VHB): en búsqueda de nuevos factores pronósticos y dianas para terapia génica

IP: -
Collaborators: Noelia Díaz Troyano
Funding agency: Instituto de Salud Carlos III
Funding: 60000
Reference: INT19/00060
Duration: 01/06/2020 - 30/06/2021

Related news

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

Docetaxel, carried by Soluplus, proved to be the most effective and least toxic combination to cross the blood-brain barrier and attack the tumour directly.

Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.

Related professionals

Mario Marotta Baleriola

Mario Marotta Baleriola

Postdoctoral researcher
Bioengineering, Cell Therapy and Surgery in Congenital Malformations
Read more
Lluisa Montesinos Magraner

Lluisa Montesinos Magraner

Head of group
Research Group of Physical Medicine and Rehabilitation
Read more
Carmen Llorens Cebriá

Carmen Llorens Cebriá

Tècnic/a Superior Recerca
High Technology Unit (UAT)
Preclinical Core Facilities
External Strategy Directorate
Read more
Virginia Robles Alonso

Virginia Robles Alonso

Predoctoral researcher
Physiology and Pathophysiology of the Digestive Tract
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.